The purpose of this study is to calculate the pharmacokinetics (concentration of compound in and rate of excretion from the blood) following a very low dose of compound which will not have any pharmacological activity and to monitor for the safety and tolerability of each of the compounds in the study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
40
single intravenous infusion of 100 microgram
single oral administration of 100 microgram
single intravenous infusion of 100 microgram of PF-05089771
Pfizer Investigational Site
Edinburgh, United Kingdom
Safety and tolerability (heart rate, blood pressure, QTcF, clinical chemistry)
Time frame: up to 3 days post dose
pharmacokinetics of each of the four compounds measuring Clearance, volume of distribution, elimination half life and area under the effect curve
Time frame: up to 3 days post dose
safety and tolerability of each of the four compounds (heart rate, blood pressure, QTcF, clinical chemistry)
Time frame: up to 3 days post dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
single oral administration of 100 microgram PF-05089771
single intravenous administration of 100 microgram PF-05150122
single oral administration of 100 microgram PF-05150122
single intravenous infusion of 100 microgram PF-05241328
single oral administration 100 microgram PF-05241328